Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 3
2018 3
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Introduction of biosimilar insulins in Europe.
Davies M, Dahl D, Heise T, Kiljanski J, Mathieu C. Davies M, et al. Diabet Med. 2017 Oct;34(10):1340-1353. doi: 10.1111/dme.13400. Epub 2017 Jul 16. Diabet Med. 2017. PMID: 28608570 Free PMC article. Review.
Regulatory approval of the first biosimilar insulin in Europe, LY2963016 insulin glargine (Abasaglar() ), in 2014 expanded the treatment options available to people with diabetes. ...
Regulatory approval of the first biosimilar insulin in Europe, LY2963016 insulin glargine (Abasaglar() ), in 2014 expanded the treatm …
LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes.
Lamb YN, Syed YY. Lamb YN, et al. BioDrugs. 2018 Feb;32(1):91-98. doi: 10.1007/s40259-018-0259-4. BioDrugs. 2018. PMID: 29368288 Review.
Subcutaneous once-daily LY2963016 insulin glargine (LY insulin glargine) [Abasaglar() (EU); Basaglar() (USA)] has been approved in the EU as a biosimilar to reference insulin glargine (Lantus()), and in the USA as a follow-on biologic to reference insulin glargine, for use …
Subcutaneous once-daily LY2963016 insulin glargine (LY insulin glargine) [Abasaglar() (EU); Basaglar() (USA)] has been approved in th …
Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR()/ABASAGLAR()) approved in the European Union.
Byrd RA, Owens RA, Blackbourne JL, Coutant DE, Farmen MW, Michael MD, Moyers JS, Schultze AE, Sievert MK, Tripathi NK, Vahle JL. Byrd RA, et al. Regul Toxicol Pharmacol. 2017 Aug;88:56-65. doi: 10.1016/j.yrtph.2017.05.013. Epub 2017 May 17. Regul Toxicol Pharmacol. 2017. PMID: 28526658
Basaglar()/Abasaglar() (Lilly insulin glargine [LY IGlar]) is a long-acting human insulin analogue drug product granted marketing authorisation as a biosimilar to Lantus() (Sanofi insulin glargine [SA IGlar]) by the European Medicines Agency. ...
Basaglar()/Abasaglar() (Lilly insulin glargine [LY IGlar]) is a long-acting human insulin analogue drug product granted marketing aut …
[LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union].
Altman JJ, Chevalier N, Delemer B, Travert F, Benabbad I. Altman JJ, et al. Presse Med. 2018 Oct;47(10):854-866. doi: 10.1016/j.lpm.2018.06.004. Epub 2018 Sep 25. Presse Med. 2018. PMID: 30262205 Free article. Review. French.
The development of generics requires bioequivalence studies in healthy volunteers. Abasaglar(), a biosimilar of insulin glargine, is the first insulin biosimilar approved in the European Union. ...
The development of generics requires bioequivalence studies in healthy volunteers. Abasaglar(), a biosimilar of insulin glargine, is …
Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study.
Torre E, Bruno GM, Di Matteo S, Martinotti C, Valentino MC, Bottaro LC, Colombo GL. Torre E, et al. Clinicoecon Outcomes Res. 2020 Apr 8;12:177-189. doi: 10.2147/CEOR.S240183. eCollection 2020. Clinicoecon Outcomes Res. 2020. PMID: 32308446 Free PMC article.
MATERIAL AND METHOD: In our analysis, we have applied the cost-utility technique to the above reported clinical outcomes and compared the global costs of dulaglutide versus sulfonylurea or basal insulin, all in add-on with metformin. We have chosen gliclazide, as a sulfonylurea a …
MATERIAL AND METHOD: In our analysis, we have applied the cost-utility technique to the above reported clinical outcomes and compared the gl …
Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus.
Evans M, Chubb B, Gundgaard J. Evans M, et al. Diabetes Ther. 2017 Apr;8(2):275-291. doi: 10.1007/s13300-017-0236-9. Epub 2017 Feb 16. Diabetes Ther. 2017. PMID: 28210866 Free PMC article.
Scenario analyses versus two new-to-market basal insulin analogues indicate that in patients with T1DM and T2DM(BOT), IDeg is likely to be highly cost-effective versus IGlar biosimilar Abasaglar() and dominant versus IGlar U300 (Toujeo()). In T2DM(B/B), IDeg is likely to b …
Scenario analyses versus two new-to-market basal insulin analogues indicate that in patients with T1DM and T2DM(BOT), IDeg is likely to be h …